Intrinsiqq
Processa Pharmaceuticals Inc. logo

Processa Pharmaceuticals Inc. Insider Trading

PCSA

Compare
Last 12 months

Insiders bought 203K on the open market and sold nothing.

Net open-market
+203K
41 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
9 / 0
executives and directors
Last open-market buy
Jul 2026
Jul 1, 2026

Get an email when PCSA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jul 1
    George K Ng
    Chief Executive Officer · bought 3,057 at $1.93
    6K
    18% of stake
  • Jun 30
    Wendy Guy
    Chief Administrative Officer · bought 2,436 at $1.93
    5K
    20% of stake
  • Jun 30
    Patrick Lin
    Chief Business - Strategy Off · bought 2,106 at $1.93
    4K
    17% of stake
  • Jun 30
    Russell Skibsted
    Chief Financial Officer · bought 3,277 at $1.93
    6K
    24% of stake
  • Jun 30
    David Young
    Pres. Research & Development · bought 2,531 at $1.93
    5K
    12% of stake
  • Jun 15
    David Young
    Pres. Research & Development · bought 2,067 at $2.22
    5K
    10% of stake
  • Jun 15
    Russell Skibsted
    Chief Financial Officer · bought 2,654 at $2.22
    6K
    25% of stake
  • Jun 15
    George K Ng
    Chief Executive Officer · bought 2,465 at $2.22
    5K
    17% of stake
  • Jun 15
    Patrick Lin
    Chief Business - Strategy Off · bought 1,831 at $2.22
    4K
    17% of stake
  • Jun 15
    Wendy Guy
    Chief Administrative Officer · bought 2,118 at $2.22
    5K
    21% of stake
  • May 29
    David Young
    Pres. Research & Development · bought 1,786 at $2.57
    5K
    10% of stake
  • May 29
    Russell Skibsted
    Chief Financial Officer · bought 2,292 at $2.57
    6K
    27% of stake
  • May 29
    George K Ng
    Chief Executive Officer · bought 2,129 at $2.57
    5K
    18% of stake
  • May 29
    Patrick Lin
    Chief Business - Strategy Off · bought 1,582 at $2.57
    4K
    17% of stake
  • May 29
    Wendy Guy
    Chief Administrative Officer · bought 1,829 at $2.57
    5K
    22% of stake
  • May 15
    George K Ng
    Chief Executive Officer · bought 1,843 at $2.97
    5K
    18% of stake
  • May 15
    David Young
    Pres. Research & Development · bought 1,545 at $2.97
    5K
    9.5% of stake
  • May 15
    Patrick Lin
    Chief Business - Strategy Off · bought 1,369 at $2.97
    4K
    17% of stake
  • May 15
    Wendy Guy
    Chief Administrative Officer · bought 1,583 at $2.97
    5K
    23% of stake
  • May 15
    Russell Skibsted
    Chief Financial Officer · bought 1,984 at $2.97
    6K
    31% of stake
  • Apr 30
    Sian Bigora
    Chief Development Officer · bought 1,971 at $2.71
    5K
    34% of stake
  • Apr 30
    David Young
    Pres. Research & Development · bought 1,706 at $2.69
    5K
    12% of stake
  • Apr 30
    Russell Skibsted
    Chief Financial Officer · bought 2,190 at $2.69
    6K
    51% of stake
  • Apr 30
    George K Ng
    Chief Executive Officer · bought 2,034 at $2.69
    5K
    25% of stake
  • Apr 30
    Patrick Lin
    Chief Business - Strategy Off · bought 1,511 at $2.69
    4K
    23% of stake
  • Apr 30
    Wendy Guy
    Chief Administrative Officer · bought 1,748 at $2.69
    5K
    35% of stake
  • Apr 15
    George K Ng
    Chief Executive Officer · bought 1,843 at $2.97
    5K
    29% of stake
  • Apr 15
    David Young
    Pres. Research & Development · bought 1,545 at $2.97
    5K
    12% of stake
  • Apr 15
    Patrick Lin
    Chief Business - Strategy Off · bought 1,369 at $2.97
    4K
    27% of stake
  • Apr 15
    Wendy Guy
    Chief Administrative Officer · bought 1,583 at $2.97
    5K
    46% of stake
  • Apr 15
    Sian Bigora
    Chief Development Officer · bought 1,799 at $2.97
    5K
    45% of stake
  • Apr 15
    Russell Skibsted
    Chief Financial Officer · bought 1,984 at $2.97
    6K
    85% of stake
  • Mar 31
    George K Ng
    Chief Executive Officer · bought 2,136 at $2.54
    5K
    50% of stake
  • Mar 31
    James R Neal
    Director · bought 789 at $2.54
    2K
    2721% of stake
  • Mar 31
    David Young
    Pres. Research & Development · bought 1,810 at $2.54
    5K
    16% of stake
  • Mar 31
    Russell Skibsted
    Chief Financial Officer · bought 2,324 at $2.54
    6K
    New position
  • Mar 31
    Geraldine Pannu
    Director · bought 2,072 at $2.54
    5K
    1786% of stake
  • Mar 31
    Patrick Lin
    Chief Business - Strategy Off · bought 1,603 at $2.54
    4K
    46% of stake
  • Mar 31
    Wendy Guy
    Chief Administrative Officer · bought 1,854 at $2.54
    5K
    117% of stake
  • Mar 31
    Sian Bigora
    Chief Development Officer · bought 2,107 at $2.54
    5K
    113% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PCSA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PCSA

CompareIntrinsic value
RLMDRelmada Therapeutics Inc.
$2.62-15.76%10
ASBPAspire Biopharma Holdings Inc.
$7.13-6.80%20
TCRTAlaunos Therapeutics Inc.
$1.66+4.40%10
AZTRAzitra Inc.
$0.52-2.64%20
GNLXGenelux Corp.
$2.17-4.82%10
RGPXRegenerex Pharma, Inc.
No recent price15
ATOSAtossa Therapeutics Inc
$1.60-8.86%10
CRVOCervoMed Inc.
$1.45+8.65%10

Spot a number that looks wrong? Check it in PCSA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PCSA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.